ClinConnect ClinConnect Logo
Search / Trial NCT05625802

Erector Spinae Plane Block for Uncomplicated Renal Colic

Launched by UNIVERSITY OF MICHIGAN · Nov 22, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Erector Spinae Plane Block Emergency Department Ropivacaine

ClinConnect Summary

This clinical trial is investigating a new way to help manage pain from kidney stones, specifically using a method called the Erector Spinae Plane Block (ESPB). The goal is to see how effective this treatment is for relieving pain and to check for any side effects that participants might experience. The study is currently looking for participants aged 65 to 74 who have confirmed kidney stones and have received pain medication in the emergency department.

To be eligible for this trial, participants should not be pregnant or breastfeeding, have certain medical conditions, or take specific medications that could interfere with the study. If you join the trial, you can expect to receive the ESPB treatment and be monitored for its effectiveness and any possible side effects. This could be an opportunity to help improve pain management for kidney stones while contributing to important research.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Imaging confirmation of urolithiasis on the index encounter or prior encounter within 7 days
  • Patient received one dose of parenteral pain medication in the emergency department (ED)
  • Exclusion Criteria:
  • Pregnancy or breastfeeding
  • Prisoner or incarcerated individual
  • Therapeutic anticoagulation or coagulopathy.
  • Active treatment for urinary tract infection (either acute infection or chronic therapy)
  • Prior spinal surgery in the thoracic region
  • Allergy to local anesthetic or prior local anesthetic
  • Soft tissue infection overlying the injection site
  • Positive for coronavirus
  • Inability to communicate verbally or read/write in English
  • Currently taking strong CYP1A2 inhibitor (fluvoxamine, amiodarone, fluoroquinolones, etc.)
  • Glucose-6-phosphate dehydrogenase deficiency (G6PD)

About University Of Michigan

The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.

Locations

Ann Arbor, Michigan, United States

Patients applied

0 patients applied

Trial Officials

Chris Fung

Study Chair

University of Michigan

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials